Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index
Biomolecules and Biomedicine · 2024
DOI: 10.17305/bb.2024.11155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Nulifer Kilic Durankus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkiye. Hauptthemen laut MEDLINE: Osteoradionecrosis, Chemoradiotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteoradionecrosis (ORN) is a severe complication that can arise in patients with nasopharyngeal carcinoma due to the aggressive nature of chemoradiotherapy treatment. The purpose of our study was to assess the utility of the recently introduced CARWL index, which integrates the C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL), in predicting the risk of ORN in patients with locoregionally advanced nasopharyngeal cancer (LA-NPC) undergoing concurrent chemoradiotherapy (CCRT). We conducted a retrospective cohort analysis on 304 patients with LA-NPC treated with CCRT. Patients were categorized into CARWL index groups based on CAR (cut-off: 3.0) and SWL (weight loss > 5% over the past six months): CARWL-0 (CAR < 3.0, SWL ≤ 5%), CARWL-1 (CAR < 3.0 with SWL > 5% or CAR ≥ 3.0 with SWL ≤ 5%), and CARWL-2 (CAR ≥ 3.0 and SWL > 5%). The primary endpoint was the incidence of ORN in each CARWL index group. At a median follow-up of 67.2 months, 28 patients (9.2%) developed ORN. The incidence of ORN was 2.1%, 9.4%, and 16.3% in the CARWL-0, CARWL-1, and CARWL-2 groups, respectively (P < 0.001). Multivariate analysis identified smoking status (HR: 2.58, P = 0.034), N-stage (HR: 1.96, P = 0.008), T-stage (HR: 1.84, P = 0.017), pre-CCRT tooth extraction status (HR: 5.81, P < 0.001), post-CCRT tooth extraction status (HR: 6.82, P < 0.001), mandibular V55.8 Gy (HR: 6.12, P < 0.001), and CARWL score (HR: 5.67, P = 0.002) as significant predictors of ORN. The CARWL index is a reliable predictive tool for evaluating the risk of ORN in LA-NPC patients undergoing CCRT. If further validated, its use in clinical settings could aid in the early identification of high-risk patients and enable the implementation of personalized preventive strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkiye.
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkiye.
- Department of Periodontology, Faculty of Dentistry, Baskent University, Ankara, Turkiye.
- Department of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye.
- Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkiye.
Zitieren
APA
Kilic Durankus, N., Somay, E., Bascil, S., Senyurek, S., Ozturk, D., Selek, U., & Topkan, E. (2024). Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.11155
Vancouver
Kilic Durankus N, Somay E, Bascil S, Senyurek S, Ozturk D, Selek U, et al. Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.11155
BibTeX
@article{KilicDurankus2024,
author = {Kilic Durankus, Nulifer and Somay, Efsun and Bascil, Sibel and Senyurek, Sukran and Ozturk, Duriye and Selek, Ugur and Topkan, Erkan},
title = {Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index},
journal = {Biomolecules and Biomedicine},
year = {2024},
doi = {10.17305/bb.2024.11155}
}
EUVIMED